Background/Aims: The risk factors for pituitary hormone dysfunction (PHD) in children with optic nerve hypoplasia (ONH) are not well understood. This study identified the type, timing, and predictors of PHD in children with ONH. Methods: ONH patient charts were reviewed retrospectively. The incidence rate of PHD was calculated assuming a Poisson distribution. Predictors of PHD were identified through a multivariable Cox proportional hazards model. Results: Among 144 subjects with ONH, 49.3% (n = 71) developed PHD over 614.7 person-years of follow-up. The incidence was 11.55 (95% confidence interval [CI]: 9.02–14.57/100 person-years). The median time to first PHD was 2.88 (interquartile range: 0.02–18.72) months. Eighty-two percent developed their first PHD by their 5th and 90% by their 10th birthday, and 89% within 5 years of ONH diagnosis. Prematurity (adjusted hazard ratio [aHR]: 0.33; 95% CI: 0.1–1.07), blindness (aHR: 1.72; 95% CI: 1.03–2.86), maternal substance abuse (aHR: 1.51; 95% CI: 0.91–2.48), abnormal posterior pituitary (aHR: 3.8; 95% CI: 2.01–7.18), and hypoplastic/absent anterior pituitary (aHR: 2.52; 95% CI: 1.29–4.91) were significant predictors of PHD. Conclusions: The clinical predictors of PHD included blindness, pituitary gland abnormalities, and maternal substance abuse. These predictors help clinical decision-making related to the need for and frequency of hormone testing in pediatric patients with ONH.

Keywords:
Optic nerve hypoplasia, Pituitary gland, Hormone deficiency, Risk factors, Incidence rate
1.
Borchert M, Garcia-Filion P: The syndrome of optic nerve hypoplasia. Curr Neurol Neurosci Rep 2008; 8: 395–403.
2.
Cemeroglu AP, Coulas T, Kleis L: Spectrum of clinical presentations and endocrinological findings of patients with septo-optic dysplasia: a retrospective study. J Pediatr Endocrinol Metab 2015; 28: 1057–1063.
3.
Mohney B, Young R, Diehl N: Incidence and associated endocrine and neurologic abnormalities of optic nerve hypoplasia. JAMA Ophthalmol 2013; 131: 898–902.
4.
McNay D, Turton JP, Kelberman D, Woods KS, Brauner R, Papadimitriou A, Keller E, Keller A, Haufs N, Krude H, Shalet SM, Dattani MT: HESX1 mutations are an uncommon cause of septooptic dysplasia and hypopituitarism. J Clin Endocrinol Metab 2007; 92: 691–697.
5.
Thomas PQ, Dattani MT, Brickman JM, McNay D, Warne G, Zacharin M, Cameron F, Hurst J, Woods K, Dunger D, Stanhope R, Forrest S, Robinson IC, Beddington RS: Heterozygous HESX1 mutations associated with isolated congenital pituitary hypoplasia and septo-optic dysplasia. Hum Mol Genet 2001; 10: 39–45.
6.
Garcia-Filion P, Borchert M: Prenatal determinants of optic nerve hypoplasia: review of suggested correlates and future focus. Surv Ophthalmol 2013; 58: 610–619.
7.
Oatman O, McClellan D, Olson M, Garcia-Filion P: Endocrine and pubertal disturbances in optic nerve hypoplasia, from infancy to adolescence. Int J Pediatr Endocrinol 2015; 2015: 8.
8.
Birkebaek NH, Patel L, Wright NB, Grigg JR, Sinha S, Hall CM, Price DA, Lloyd IC, Clayton PE: Endocrine status in patients with optic nerve hypoplasia: relationship to midline central nervous system abnormalities and appearance of the hypothalamic-pituitary axis on magnetic resonance imaging. J Clin Endocrinol Metab 2003; 88: 5281–5286.
9.
Ramakrishnaiah RH, Shelton JB, Glasier CM, Phillips PH: Reliability of magnetic resonance imaging for the detection of hypopituitarism in children with optic nerve hypoplasia. Ophthalmology 2014; 121: 387–391.
10.
Phillips PH, Spear C, Brodsky MC: Magnetic resonance diagnosis of congenital hypopituitarism in children with optic nerve hypoplasia. J AAPOS 2001; 5: 275–280.
11.
Skarf B, Hoyt CS: Optic nerve hypoplasia in children. Association with anomalies of the endocrine and CNS. Arch Ophthalmol 1984; 102: 62–67.
12.
Garcia ML, Ty EB, Taban M, Rothner D, Rogers D, Traboulsi E: Systemic and ocular findings in 100 patients with optic nerve hypoplasia. J Child Neurol 2006; 21: 949–956.
13.
Garcia-Filion P, Epport K, Nelson M, Azen C, Geffner ME, Fink C, Borchert M: Neuroradiographic, endocrinologic, and ophthalmic correlates of adverse developmental outcomes in children with optic nerve hypoplasia: a prospective study. Pediatrics 2008; 121: 653–659.
14.
Ryabets-Lienhard A, Stewart C, Borchert M, Geffner M: The optic nerve hypoplasia spectrum. Review of the literature and clinical guidelines. Adv Pediatr 2016; 63: 127–146.
15.
Goh YW, Andrew D, McGhee C, Dai S: Clinical and demographic associations with optic nerve hypoplasia in New Zealand. Br J Ophthalmol 2014; 98: 1364–1367.
16.
Haddad NG, Eugster EA: Hypopituitarism and neurodevelopmental abnormalities in relation to central nervous system structural defects in children with optic nerve hypoplasia. J Pediatr Endocrinol Metab 2005; 858: 853–858.
17.
Hatton DD, Ivy SE, Boyer C: Severe visual impairments in infants and toddlers in the United States. J Vis Impair Blind 2013; 107: 325–337.
18.
Ahmed T, Garcia-Filion P, Borchert M, Kaufman F, Burkett L, Geffner M: Endocri-nological and auxological abnormalities in young children with optic nerve hypoplasia: a prospective study. J Pediatr 2006; 148: 78–84.
19.
Samarawickrama C, Huynh SC, Liew G, Burlutsky G, Mitchell P: Birth weight and optic nerve head. Ophthalmology 2009; 116: 1112–1118.
20.
Tong AY, El-Dairi M, Maldonado RS, Rothman AL, Yuan EL, Stinnett SS, Kupper L, Cotton CM, Gustafson KE, Goldstein RF, Freedman SF, Toth CA: Evaluation of optic nerve development in preterm and term infants using handheld spectral-domain optical coherence tomography. Ophthalmology 2014; 121: 1818–1826.
21.
Rapoport RM, Yoon S, Zuccarello M: Cocaine constrictor mechanisms of the cerebral vasculature. J Cardiovasc Pharmacol 2016; 67: 442–450.
22.
Lubinsky MS: Hypothesis: septo-optic dysplasia is a vascular disruption sequence. Am J Med Genet 1997; 69: 235–236.
23.
Insel JR, Dhanjal N: Pituitary infarction resulting from intranasal cocaine abuse. Endocr Pract 2004; 10: 478–482.
© 2017 S. Karger AG, Basel
2017
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.